(Q34349952)

1 August 2017

title

Cutaneous dermatomyositis: an updated review of treatment options and internal associations (English)

1 reference

1 August 2017

0 references

Alisa N Femia

1

1 reference

1 August 2017

Ruth Ann Vleugels

series ordinal

2

1 reference

1 August 2017

Jeffrey P Callen

series ordinal

3

1 reference

1 August 2017

publication date

1 August 2013

1 reference

American Journal of Clinical Dermatology

1 August 2017

published in

1 reference

1 August 2017

volume

14

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

291-313

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

1 August 2017

1 reference

Review: An update on inflammatory and autoimmune myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Polymyositis and dermatomyositis: pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Polymyositis and dermatomyositis (first of two parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Polymyositis and dermatomyositis (second of two parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The management of dermatomyositis: current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Quality of life in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Photosensitivity in collagen vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Management of cutaneous dermatomyositis: current therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Topical tacrolimus treatment in a patient with dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Successful treatment of amyopathic dermatomyositis with topical tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Bullous allergic contact dermatitis to lidocaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Adverse effects of corticosteroids: I. Topical and intralesional

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Use of antimalarials in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Dermatomyositis: a dermatology-based case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Methotrexate in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Inflammatory myopathies: management of steroid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Treatment of dermatomyositis with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Methotrexate treatment of recalcitrant childhood dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Oral effects of low-dose methotrexate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Lymphoma risk in psoriasis: results of the PUVA follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Mycophenolate mofetil in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Mycophenolate mofetil for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Mycophenolate mofetil in juvenile dermatomyositis: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Azathioprine in dermatology: the past, the present, and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Dermatological uses of high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Not all intravenous immunoglobulin preparations are equally well tolerated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Therapy of polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Immunotherapy of myositis: issues, concerns and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Dapsone and sulfones in dermatology: overview and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Cutaneous involvement of dermatomyositis can respond to Dapsone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

TNF-α impairs differentiation and function of TGF-β-induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Therapeutic advances in myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

A randomized, pilot trial of etanercept in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Treatment of early and refractory dermatomyositis with infliximab: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Tumor necrosis factor inhibitor-associated dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Rituximab in the treatment of refractory dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Successful treatment of cardiac involvement in dermatomyositis with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Rituximab treatment in patients with refractory inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The use of cyclosporine in dermatology: part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Cyclosporin in the management of polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Successful treatment with tacrolimus in a case of refractory dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Treatment of refractory juvenile dermatomyositis with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Sirolimus (rapamycin): from the soil of Easter Island to a bright future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Leflunomide as adjuvant treatment of dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Improvement in dermatomyositis rash associated with the use of antiestrogen medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein–Barr virus connection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The value of malignancy evaluation in patients with dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Occult malignant tumors in dermatologic disease. The futility of radiological search

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Ovarian malignancy in patients with dermatomyositis and polymyositis: a retrospective analysis of fourteen cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

A systematic review of juvenile-onset clinically amyopathic dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Morbidity and mortality in adult polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

The lung is involved in juvenile dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0028-6

10.1007/S40257-013-0028-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1010130352

0 references

1 reference